2023年7月28日

免疫治療完成首輪融資,籌集1200萬美元由西元GBA基金家裏»新聞»免疫治療係列完成一輪融資,籌集1200萬美元由西元GBA基金byarchywordys沒有評論讀香港行政區域媒體推廣- 2023年7月27日生物免疫治療適合在一係列成功籌集了1200萬美元資金2700萬美元。由西元大灣地區基金- GBA(大Vinh地區(包括香港、澳門和廣東省9大城市)由戈壁合夥人GBA管理。籌集的資金將被用於免疫治療加速DNA疫苗和抗體的發展,以及準備一個在香港首次公開發行(IPO)。免疫治療的重點是研究和開發(研發)的免疫療法對癌症、炎症性疾病和傳染性疾病的基礎上“PD-1增強DNA疫苗平台”和“抗體平台”。Anti-Δ42PD1”專利和兩個DNA候選疫苗,ICVAX ICCOV,,目前正在進行臨床試驗。夏博士,首席執行官(CEO)的免疫治療,說:“這一輪融資是一個轉折點在免疫治療的商業擴張。我們感到很榮幸大灣區西元基金會的大力支持,這證實了我們的科學價值和研發。免疫治療將繼續研發的最前沿的創新DNA藥物、抗體和免疫治療,進行新的和有效的疫苗研發技術來加強我們阿森納對抗癌症。和傳染病”。Chibo唐先生,高級經理戈壁合夥人GBA,“傳染性疾病是一個普遍問題,威脅全球公共衛生多年,進一步強調了COVID-19大流行。 We believe that Immuno Cure’s technologies have innovative applications in immunotherapy for not only infectious diseases, but also cancer and other diseases, and have the potential to truly change the world.” . ICVAX, a therapeutic DNA vaccine candidate against HIV/AIDS, was developed with the aim of generating specific T cells, with a multifunctional virus that reacts extensively to achieve a cure for HIV/AIDS. . The phase I clinical trial of ICVAX, underway in Shenzhen, was designed as a randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of the drug. ICVAX out of 45 volunteers are stable HIV/AIDS patients on antiretroviral therapy. ICCOV, a candidate DNA vaccine for the prevention of COVID-19, has participated in the Phase IIa clinical trial in Hong Kong, designed as an open-label study to evaluate the immunogenicity and safety of ICCOV as a booster vaccine in a total of 60 healthy adult volunteers aged 18 to 75 years Furthermore, Immuno Cure has achieved remarkable achievements on the Anti-Δ42PD1 Antibody platform, using antibodies targeting Δ42PD1, a homologous programmed cell death protein 1 (PD-1) recently discovered, to restore the function of killer T cells, a type of immune cells that are needed to kill cancer cells, to treat cancers like liver cancer and lung cancer. colorectal mail. Hashtag: #ImmunoCure #醫克生物 #醫克生物 Information about Immuno Cure Immuno Cure is a clinical stage biotechnology group based in Hong Kong Science Park, focused on research and development of immunotherapies for cancer, inflammatory and infectious diseases infection based on the patented PD-1 enhanced DNA vaccine and Anti-42PD1 Antibody; with two DNA vaccine candidates currently in clinical trials. Official website www.immunocure.hk Information about Gobi GABA Gobi Partners GBA (Gobi GBA) was established in 2016 as part of Asia’s leading venture capital platform Gobi Partners. Gobi GBA is the sole general partner (GP) of Alibaba Hong Kong Entrepreneurs Fund (AEF) and AEF Greater Bay Area Fund (AEF GBA Fund) and has established a partnership strategic partnership with other well-known financial institutions such as HSBC and Hang Seng Bank. As of this year, Gobi GBA has invested in over 70 startups across the Greater Bay Area and has driven the growth of 7 unicorns (unicorn is a start-up with a market capitalization of 1 billion USD or more) including Airwallex, Amber, Animoca Brands, GoGoX, Prenetics… Official website: https://gobi.vc